CA3195410A1 - Therapeutic radiolabelled conjugates and their use in therapy - Google Patents

Therapeutic radiolabelled conjugates and their use in therapy

Info

Publication number
CA3195410A1
CA3195410A1 CA3195410A CA3195410A CA3195410A1 CA 3195410 A1 CA3195410 A1 CA 3195410A1 CA 3195410 A CA3195410 A CA 3195410A CA 3195410 A CA3195410 A CA 3195410A CA 3195410 A1 CA3195410 A1 CA 3195410A1
Authority
CA
Canada
Prior art keywords
compound
formula
nodaga
therapeutic
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3195410A
Other languages
English (en)
French (fr)
Inventor
Philip Hogg
Ivan HO SHON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903727A external-priority patent/AU2020903727A0/en
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of CA3195410A1 publication Critical patent/CA3195410A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3195410A 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy Pending CA3195410A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903727 2020-10-14
AU2020903727A AU2020903727A0 (en) 2020-10-14 Conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Publications (1)

Publication Number Publication Date
CA3195410A1 true CA3195410A1 (en) 2022-04-21

Family

ID=81207378

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3195410A Pending CA3195410A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Country Status (10)

Country Link
US (1) US20230398240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228710A4 (cg-RX-API-DMAC7.html)
JP (1) JP7890301B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130610A (cg-RX-API-DMAC7.html)
CN (1) CN116472068A (cg-RX-API-DMAC7.html)
AU (1) AU2021359638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195410A1 (cg-RX-API-DMAC7.html)
IL (1) IL302033A (cg-RX-API-DMAC7.html)
MX (1) MX2023004327A (cg-RX-API-DMAC7.html)
WO (1) WO2022077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152229A1 (en) 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US20250269072A1 (en) * 2021-10-14 2025-08-28 Centenary Institute Of Cancer Medicine And Cell Biology Processes for preparing radiolabelled conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
LT3275883T (lt) 2015-03-25 2021-08-25 Fujifilm Corporation Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US20220152229A1 (en) * 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents

Also Published As

Publication number Publication date
CN116472068A (zh) 2023-07-21
JP7890301B2 (ja) 2026-07-14
IL302033A (en) 2023-06-01
KR20230130610A (ko) 2023-09-12
US20230398240A1 (en) 2023-12-14
MX2023004327A (es) 2023-08-30
EP4228710A4 (en) 2025-04-09
EP4228710A1 (en) 2023-08-23
WO2022077068A1 (en) 2022-04-21
JP2023547954A (ja) 2023-11-14
AU2021359638A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
ES2736134T3 (es) Derivado peptídico de tiourea, compuesto marcado con radioisótopos que contiene el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para tratar o diagnosticar el cáncer de próstata
EP3856261A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
US12296030B2 (en) Conjugates and their use as imaging agents
AU2019345320B2 (en) Methods of treating cancer
AU2009200201A1 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20230398240A1 (en) Therapeutic radiolabelled conjugates and their use in therapy
JP2023523226A (ja) Psma結合リガンドを放射標識するための方法及びそのキット
JP2022549258A (ja) セラノスティックスとして使用するための放射性標識grprアンタゴニスト
US20250269072A1 (en) Processes for preparing radiolabelled conjugates
CN120344273A (zh) 二聚体放射性药物、其组合物及其用途
JP2024539952A (ja) 放射性核種錯体の組み合わせ療法
HK40008701A (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240925

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240925

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251010

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251212

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122